Michael A Henos Net Worth

The estimated Net Worth of Michael A Henos is at least $317 Tisíc dollars as of 19 December 2014. Michael Henos owns over 21,257 units of GlycoMimetics Inc stock worth over $75,113 and over the last 11 years Michael sold GLYC stock worth over $241,433.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Michael Henos GLYC stock SEC Form 4 insiders trading

Michael has made over 4 trades of the GlycoMimetics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Michael sold 21,257 units of GLYC stock worth $181,110 on 19 December 2014.

The largest trade Michael's ever made was selling 21,257 units of GlycoMimetics Inc stock on 19 December 2014 worth over $181,110. On average, Michael trades about 5,068 units every 33 days since 2014. As of 19 December 2014 Michael still owns at least 469,454 units of GlycoMimetics Inc stock.

You can see the complete history of Michael Henos stock trades at the bottom of the page.

What's Michael Henos's mailing address?

Michael's mailing address filed with the SEC is C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG, MD, 20879.

Insiders trading at GlycoMimetics Inc

Over the last 11 years, insiders at GlycoMimetics Inc have traded over $15,299,593 worth of GlycoMimetics Inc stock and bought 10,868,557 units worth $48,421,008 . The most active insiders traders include Scott D Sandell, Peter J Barris a M James Barrett. On average, GlycoMimetics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $38,210. The most recent stock trade was executed by Public Equities, L.P.Invus ... on 7 August 2024, trading 322,361 units of GLYC stock currently worth $61,249.

What does GlycoMimetics Inc do?

at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.

Complete history of Michael Henos stock trades at GlycoMimetics Inc

GlycoMimetics Inc executives and stock owners

GlycoMimetics Inc executives and other stock owners filed with the SEC include:

• Rachel King,
  President, Chief Executive Officer, Co-Founder, Director
• Brian Hahn,
  Chief Financial Officer
• Helen Thackray,
  Senior Vice President - Clinical Development, Chief Medical Officer
• John Magnani,
  Co-Founder, Senior Vice President, Chief Scientific Officer
• Rachel K. King,
  Pres, CEO & Director
• Brian M. Hahn,
  Sr. VP & CFO
• Timothy Pearson,
  Independent Chairman of the Board
• Daniel Junius,
  Independent Director
• Mark Goldberg,
  Independent Director
• Scott Jackson,
  Independent Director
• Patricia Andrews,
  Independent Director
• Scott Koenig,
  Independent Director
• Armand Girard,
  Senior Vice President, Chief Business Officer
• Bruce Johnson,
  Sr. VP & Chief Commercial Officer
• Armand Girard,
  Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel.
• Dr. John L. Magnani,
  Sr. VP of Research & Chief Scientific Officer
• Harout Semerjian,
  CEO, Pres & Director
• Dr. Eric J. Feldman M.D.,
  Sr. VP & Chief Medical Officer
• Christian Dinneen-Long,
  VP, Corp. Counsel & Corp. Sec.
• Henry Flanner,
  VP of Technical Operations
• Stephanie R. Irish,
  VP of Accounting
• Partners L P/Ilbiotechnolog...,
  
• Scott D Sandell,
  10% owner
• Franklin H Jr Top,
  Director
• Peter J Barris,
  10% owner
• Michael A Henos,
  Director
• M James Barrett,
  Director
• Enterprise Associates 10 L ...,
  
• John J. Baldwin,
  Director
• Chinmaya Rath,
  SVP and Chief Business Officer
• William M. Gust,
  Director
• Enterprise Associates 13 Lp...,
  
• Partners L P/Ilbiotechnolog...,
  
• Harout Semerjian,
  Chief Executive Officer
• Public Equities, L.P.Artal ...,
  
• Public Equities, L.P.Invus ...,
  
• Bruce S Johnson,
  SVP & Chief Commercial Officer
• Edwin Rock,
  Chief Medical Officer